A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2 Completed
92 enrolled 14 charts
Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
Phase 1/2 Terminated
33 enrolled 22 charts
Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Phase 1/2 Completed
11 enrolled 11 charts
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Phase 1/2 Completed
40 enrolled 21 charts
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Phase 1/2 Recruiting
20 enrolled
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
Phase 1/2 Terminated
10 enrolled 18 charts
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Phase 1/2 Completed
24 enrolled 8 charts
MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy
Phase 1/2 Completed
31 enrolled
MK-3475-021
Phase 1/2 Completed
267 enrolled 24 charts
TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
Phase 1/2 Terminated
25 enrolled
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Phase 1/2 Terminated
5 enrolled 9 charts
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer
Phase 1/2 Completed
222 enrolled 23 charts
CheckMate370
Phase 1/2 Completed
341 enrolled 28 charts
A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer
Phase 1/2 Terminated
5 enrolled
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Phase 1/2 Completed
32 enrolled 13 charts
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Phase 1/2 Completed
38 enrolled 12 charts
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Phase 1/2 Completed
81 enrolled 14 charts
Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
Phase 1/2 Completed
41 enrolled
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
Phase 1/2 Completed
138 enrolled 40 charts
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
Phase 1/2 Terminated
22 enrolled
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
Phase 1/2 Completed
49 enrolled 8 charts
Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
Phase 1/2 Completed
46 enrolled 15 charts
Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer
Phase 1/2 Completed
64 enrolled 11 charts
A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
Phase 1/2 Completed
88 enrolled 18 charts
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
Phase 1/2 Terminated
8 enrolled 7 charts
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
Phase 1/2 Unknown
188 enrolled
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Phase 1/2 Completed
162 enrolled 11 charts
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2 Completed
53 enrolled 10 charts
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Phase 1/2 Completed
21 enrolled 8 charts
A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)
Phase 1/2 Terminated
23 enrolled 15 charts
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
Phase 1/2 Completed
66 enrolled
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase 1/2 Completed
18 enrolled 6 charts
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
Phase 1/2 Withdrawn
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
Phase 1/2 Completed
282 enrolled 25 charts
A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation
Phase 1/2 Withdrawn
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck
Phase 1/2 Completed
80 enrolled
Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 1/2 Terminated
2 enrolled
Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Phase 1/2 Completed
42 enrolled